USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
RXI PHARMACEUTICALS CORPORATION
Address:
1500 West Park Drive
Suite 210
Westborough, MA 01581-
Phone:
N/A
URL:
N/A
EIN:
120809951
DUNS:
932221729
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,467,743.00 4

Award List:

Orally administered anti-TNFalpha RNAi therapeutic for autoimmune disorders

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$597,088.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability to apply this… More

Improving self delivering properties of RNAi compounds through medicinal chemistr

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$273,824.00
Agency:
HHS
Principal Investigator:
Kevin Fettes – 508-929-3650
Abstract:
DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the… More

Novel RNAi therapy for ALS and other Neurodegenerative Disorders

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$304,559.00
Agency:
HHS
Principal Investigator:
Anastasia Khvorova – 508-767-3861
Abstract:
DESCRIPTION (provided by applicant): Project Summary / Abstract Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons in the central nervous system. Degeneration of the motor neurons results in paralysis and eventual death, usually due to… More

Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$292,272.00
Agency:
HHS
Principal Investigator:
Pamela Pavco – 508-929-3616
Abstract:
DESCRIPTION (provided by applicant): The study of retinoblastoma, a childhood tumor, has provided numerous insights into cancer biology. Perhaps most significantly, this work has revealed that cancers can develop in response to mutations in tumor suppressor genes. Tumor suppressor mutations account… More